BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#ADC–Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Orum Therapeutics team on the development of Orum�s novel targeted protein degraders (TPD) that use Orums TPD² approach, which combines the power of protein degradation with the precise tumor cell delivery mechanism of an antibody.
We are proud to have experienced leaders in drug discovery and clinical development joining our SAB, said Peter U. Park, Ph.D., Chief Scientific Officer of Orum Therapeutics. We look forward to meeting regularly and fully leveraging the teams diverse breadth of experiences as we progress the first molecule from our Antibody neoDegrader Conjugate platform, ORM-5029, into the clinic and continue to expand our pipeline in dual-precision protein degradation and broader protein homeostasis. With our scientific advisors guidance, we believe that we can bring first-in-class, dual-precision therapeutics to cancer patients quickly.
Appointed members of the newly formed Orum Therapeutics SAB include the following:
About Orum Therapeutics
Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Companys proprietary platforms generated using the TPD² approach includes the Antibody neoDegrader Conjugate (AnDC) platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, and Daejeon, South Korea. For more information, visit www.orumrx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (Orum). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the successful development and clinical benefits of novel targeted protein degraders, the frequency of SAB meetings, the commencement of first-in-human studies, the potential for development of other product candidates, the speed with which such candidates are brought to market, and the preferability of Orum products to others available are forward-looking statements. These forward-looking statements are based on managements expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertain and continually changing impacts and expected duration of the COVID-19 pandemic; the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, or negative results; competition from alternative therapies; the risk that Orum may not be able to maintain and enforce its intellectual property; the risk that product candidates may not be successfully commercialized or adopted; the availability of financing; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, health care reform, prices, and reimbursement rates. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
Contacts
Corporate: Kyuri Kim, Ph.D., Senior Manager, Business Development, Orum Therapeutics, contact@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 31 October 2024 - E-brokerage is a…
Strategic alliance poised to create new growth avenues in Thailand, Japan, and beyond. BANGKOK, THAILAND…
Leonteq announced today that it has enabled its Shari’a-compliant structured product offering on its digital…
Revolutionizing Home and Commercial Cleaning with Aqueous Ozone Solutions that are hypoallergenic & eco-friendly QUEENSLAND,…
Enjoy up to 10% rebate and chance to win business class round trip to Tokyo…
BANGKOK, THAILAND - Media OutReach Newswire - 5 November 2024 - Indorama Ventures Public Company…